FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2407424457> ?p ?o ?g. }

• W2407424457 endingPage "722b" @default.
• W2407424457 startingPage "714" @default.
• W2407424457 abstract "Sofosbuvir (SOF)- or simeprevir (SIM)-containing regimens are highly effective for treating chronic hepatitis C virus (HCV) infection. These regimens, however, are expensive. Most payers have implemented prior authorization (PA) requirements to ensure that patients who can benefit most have priority for these medications. While many Medicaid programs limit access to those with advanced disease or to members who do not have active substance use disorder (SUD), the Massachusetts Medicaid (MassHealth) Primary Care Clinician (PCC) plan does not limit access based on disease severity or presence of SUD. Evaluating PA requests for SOF and/or SIM among MassHealth members will offer a useful example of early uptake among Medicaid members and will identify patient groups who might face barriers to treatment at the provider or patient level.To (a) evaluate the percentage of MassHealth PCC members with HCV who had a PA request, along with the percentage of requests approved, and (b) identify characteristics associated with PA requests for SOF or SIM among Massachusetts Medicaid (MassHealth) members with HCV.This retrospective cohort study used enrollment, medical claims, and PA request data from MassHealth PCC members from December 6, 2012, to July 31, 2014. The sample included members with 1 or more claims with an ICD-9-CM code for HCV during this time who were continuously enrolled from December 6, 2013, to July 31, 2014. Enrollment and medical claims data for the cohort with HCV were linked to a database containing information collected from PA requests. The overall percentage of members with HCV and a PA request for SOF and/or SIM between December 6, 2013, and July 31, 2014, and the percentage of requests approved were calculated. Chi-square statistics were used to compare demographic and clinical characteristics among members with HCV who did and did not have a request. Logistic regression was used to estimate the strength of associations between patient characteristics and a PA treatment request, adjusting for clinical and demographic variables.Of 6,849 members identified with HCV, 346 (5.1%) had a PA request for SOF and/or SIM submitted to MassHealth. Compared with members with HCV who did not have a PA request for SOF or SIM, those with a PA request for these new treatments were more likely to be male (P = 0.01), older (P < 0.001), white race (P = 0.04), have standard MassHealth insurance (P = 0.01), and less likely to be homeless (P < 0.001). Members with a PA request were also more likely to have been treated for HCV in the past year and have advanced disease (hepatic decompensation, cirrhosis, or liver transplant) but less likely to have SUD (P < 0.001 for each). Ninety percent of requests for SOF or SIM were approved; few demographic or clinical characteristics were associated with approval. In adjusted analyses, predictors of PA request were aged 50-64 years (odds ratio (OR) = 2.0, 95% CI = 1.1-3.7 vs. aged < 30 years); hepatic decompensation (OR = 1.6, 95% CI = 1.2-2.3); cirrhosis (OR = 3.0, 95% CI = 2.2-4.1); liver transplant (OR = 3.0, 95% CI = 1.4-6.5); substance use (OR = 0.6, 95% CI = 0.5-0.8); recent HCV treatment (OR = 1.6, 95% CI = 1.0-2.6); comorbidity (OR = 0.95, 95% CI = 0.91-0.98) for 1-unit increase in Diagnostic Cost Group score; and care at a hospital outpatient department (OR = 2.0, 95% CI = 1.2-3.2 vs. group practice).Antiviral treatment with SOF and/or SIM was requested for a relatively small proportion of MassHealth members with HCV, with nearly all approved. Prescriber prioritization or patient barriers to care, rather than the PA process, determined access to treatment in this Medicaid population. Support may be needed to ensure patients with SUD benefit from advances in HCV treatment.No outside funding supported this research. Internal funding was provided by the Commonwealth of Massachusetts. Lavitas has received compensation from University of Tennessee Advanced Studies in Medicine for development of CPE activity. Graham has consulted for the National Viral Hepatitis Roundtable and the Department of Health and Human Services, has received payment from Medscape for CME development, and is employed by Trek Therapeutics. Jeffrey has received payment for guest lectures at Boston University and Harvard University. Study concept and design were primarily contributed by Clark and Clements, along with Graham, Lenz, and Jeffrey. Kunte collected the data, which were interpreted by Graham, Lenz, and Jeffrey, with assistance from Lavitas, Clark, and Clements. The manuscript was written primarily by Clements, along with O'Connell and assisted by Graham, and revised by all the authors." @default.
• W2407424457 created "2016-06-24" @default.
• W2407424457 creator A5001426837 @default.
• W2407424457 creator A5011285841 @default.
• W2407424457 creator A5020741172 @default.
• W2407424457 creator A5030579345 @default.
• W2407424457 creator A5031813502 @default.
• W2407424457 creator A5051742916 @default.
• W2407424457 creator A5052127730 @default.
• W2407424457 creator A5074201060 @default.
• W2407424457 date "2016-06-01" @default.
• W2407424457 modified "2023-10-12" @default.
• W2407424457 title "Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study" @default.
• W2407424457 cites W1606007006 @default.
• W2407424457 cites W1903580466 @default.
• W2407424457 cites W1963818433 @default.
• W2407424457 cites W1980154502 @default.
• W2407424457 cites W1987584200 @default.
• W2407424457 cites W2006747389 @default.
• W2407424457 cites W2013066189 @default.
• W2407424457 cites W2032624194 @default.
• W2407424457 cites W2065146174 @default.
• W2407424457 cites W2078251659 @default.
• W2407424457 cites W2081689022 @default.
• W2407424457 cites W2084417858 @default.
• W2407424457 cites W2084871902 @default.
• W2407424457 cites W2094972821 @default.
• W2407424457 cites W2111041960 @default.
• W2407424457 cites W2111044696 @default.
• W2407424457 cites W2118606767 @default.
• W2407424457 cites W2120733999 @default.
• W2407424457 cites W2124509162 @default.
• W2407424457 cites W2127189337 @default.
• W2407424457 cites W2132492420 @default.
• W2407424457 cites W2143244227 @default.
• W2407424457 cites W2147658767 @default.
• W2407424457 cites W2150652264 @default.
• W2407424457 cites W2152951811 @default.
• W2407424457 cites W2170628962 @default.
• W2407424457 cites W2411227294 @default.
• W2407424457 cites W3121271037 @default.
• W2407424457 cites W4246954218 @default.
• W2407424457 cites W4319053938 @default.
• W2407424457 cites W71332528 @default.
• W2407424457 doi "https://doi.org/10.18553/jmcp.2016.22.6.714" @default.
• W2407424457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27231798" @default.
• W2407424457 hasPublicationYear "2016" @default.
• W2407424457 type Work @default.
• W2407424457 sameAs 2407424457 @default.
• W2407424457 citedByCount "12" @default.
• W2407424457 countsByYear W24074244572017 @default.
• W2407424457 countsByYear W24074244572018 @default.
• W2407424457 countsByYear W24074244572019 @default.
• W2407424457 countsByYear W24074244572020 @default.
• W2407424457 countsByYear W24074244572022 @default.
• W2407424457 crossrefType "journal-article" @default.
• W2407424457 hasAuthorship W2407424457A5001426837 @default.
• W2407424457 hasAuthorship W2407424457A5011285841 @default.
• W2407424457 hasAuthorship W2407424457A5020741172 @default.
• W2407424457 hasAuthorship W2407424457A5030579345 @default.
• W2407424457 hasAuthorship W2407424457A5031813502 @default.
• W2407424457 hasAuthorship W2407424457A5051742916 @default.
• W2407424457 hasAuthorship W2407424457A5052127730 @default.
• W2407424457 hasAuthorship W2407424457A5074201060 @default.
• W2407424457 hasBestOaLocation W24074244571 @default.
• W2407424457 hasConcept C126322002 @default.
• W2407424457 hasConcept C159110408 @default.
• W2407424457 hasConcept C160735492 @default.
• W2407424457 hasConcept C162324750 @default.
• W2407424457 hasConcept C167135981 @default.
• W2407424457 hasConcept C2776455275 @default.
• W2407424457 hasConcept C2776534028 @default.
• W2407424457 hasConcept C2779598192 @default.
• W2407424457 hasConcept C50522688 @default.
• W2407424457 hasConcept C512399662 @default.
• W2407424457 hasConcept C71924100 @default.
• W2407424457 hasConcept C72563966 @default.
• W2407424457 hasConceptScore W2407424457C126322002 @default.
• W2407424457 hasConceptScore W2407424457C159110408 @default.
• W2407424457 hasConceptScore W2407424457C160735492 @default.
• W2407424457 hasConceptScore W2407424457C162324750 @default.
• W2407424457 hasConceptScore W2407424457C167135981 @default.
• W2407424457 hasConceptScore W2407424457C2776455275 @default.
• W2407424457 hasConceptScore W2407424457C2776534028 @default.
• W2407424457 hasConceptScore W2407424457C2779598192 @default.
• W2407424457 hasConceptScore W2407424457C50522688 @default.
• W2407424457 hasConceptScore W2407424457C512399662 @default.
• W2407424457 hasConceptScore W2407424457C71924100 @default.
• W2407424457 hasConceptScore W2407424457C72563966 @default.
• W2407424457 hasIssue "6" @default.
• W2407424457 hasLocation W24074244571 @default.
• W2407424457 hasLocation W24074244572 @default.
• W2407424457 hasLocation W24074244573 @default.
• W2407424457 hasOpenAccess W2407424457 @default.
• W2407424457 hasPrimaryLocation W24074244571 @default.
• W2407424457 hasRelatedWork W1549560353 @default.
• W2407424457 hasRelatedWork W1974171884 @default.
• W2407424457 hasRelatedWork W1999077937 @default.

• next